Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

PFI-1

Catalog No: tcsc1362

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1403764-72-6

Formula:
$C_{16}H_{17}N_3O_4S$

Pathway:
Epigenetics

Target:
Epigenetic Reader Domain

Purity / Grade:
>98%

Solubility:
DMSO : 33.33 mg/mL (95.94 mM; Need ultrasonic)

Observed Molecular Weight:
347.39

Product Description

PFI-1 is a selective **BET** (bromodomain-containing protein) inhibitor for BRD4 with **IC_{50}** of 0.22 μM in a cell-free assay.

IC50 & Target: IC50: 0.22 μM (BRD4)

In Vitro:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

PFI-1 has antiproliferative effects on leukemic cell lines and efficiently abrogates their clonogenic growth. Exposure of sensitive cell lines with PFI-1 results in G1 cell-cycle arrest, downregulation of MYC expression, as well as induction of apoptosis and induces differentiation of primary leukemic blasts. Cells exposed to PFI-1 show significant downregulation of Aurora B kinase, thus attenuating phosphorylation of the Aurora substrate H3S10, providing an alternative strategy for the specific inhibition of this well-established oncology target[1]. PFI-1 binds to with cyclic AMP response binding protein with K_d of 49 μM. PFI-1 has an EC_{50} of 1.89 μM for the inhibition of IL6 production from human blood mononuclear cells stimulated by LPS[2]. PFI-1 induces dose-dependent reduction of cell viability in T4302 $CD133^+$ cells[3]. PFI-1 inhibits the proliferating of three NET cell lines (Bon-1 derived from a pancreatic NET, and H727 and H720 derived from lung NETs)[4].

In Vivo: PFI-1 administrated (1 mg/kg, i.v.) in the rat results in the volume of distribution of 1 L/kg, the plasma clearance of 18 mL/min/kg and half-life of 1 hour. PFI-1 oral dosed (2 mg/kg) in the rat results in the oral bioavailability as low as 32%. PFI-1 administrated (2 mg/kg, s.c.) in the mouse results in a Cmax of 58 ng/mL with a Tmax of 1 h and a half-life of approximately 2 hours [2].